Oppenheimer Sticks to Their Buy Rating for Mediwound (MDWD)
TipRanks (Fri, 6-Mar 7:55 AM ET)
TipRanks (Fri, 6-Mar 6:36 AM ET)
TipRanks (Thu, 5-Mar 5:26 PM ET)
MediWound outlines $24M–$26M 2026 revenue target while expanding EscharEx clinical programs
Seeking Alpha News (Thu, 5-Mar 4:56 PM ET)
MediWound Files Annual Report on Form 20-F
Globe Newswire (Thu, 5-Mar 4:30 PM ET)
Alliance Global Partners Keeps Their Buy Rating on Mediwound (MDWD)
TipRanks (Thu, 5-Mar 2:35 PM ET)
MediWound Posts 2025 Loss but Strengthens Cash and Advances EscharEx, NexoBrid Capacity
TipRanks (Thu, 5-Mar 7:28 AM ET)
MediWound GAAP EPS of -$0.56 beats by $0.07, revenue of $1.87M misses by $0.22M
Seeking Alpha News (Thu, 5-Mar 7:06 AM ET)
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Thu, 5-Mar 7:00 AM ET)
Analysts Offer Insights on Healthcare Companies: Mediwound (MDWD) and Veeva Systems (VEEV)
TipRanks (Thu, 5-Mar 3:00 AM ET)
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Mediwound Ltd. - trades on the NASDAQ stock market under the symbol MDWD.
As of March 10, 2026, MDWD stock price declined to $17.30 with 18,770 million shares trading.
MDWD has a beta of 0.88, meaning it tends to be less sensitive to market movements. MDWD has a correlation of 0.13 to the broad based SPY ETF.
MDWD has a market cap of $222.05 million. This is considered a Small Cap stock.
Last quarter Mediwound Ltd. - reported $2 million in Revenue and -$.56 earnings per share. This fell short of revenue expectation by $-188,350 and exceeded earnings estimates by $.07.
In the last 3 years, MDWD traded as high as $24.00 and as low as $7.10.
The top ETF exchange traded funds that MDWD belongs to (by Net Assets): IWM, IZRL, IWO, VTWO, IWC.
MDWD has underperformed the market in the last year with a price return of +2.2% while the SPY ETF gained +19.5%. MDWD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -6.3% and -4.7%, respectively, while the SPY returned 0.0% and -0.2%, respectively.
MDWD support price is $17.07 and resistance is $17.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDWD shares will trade within this expected range on the day.